166 related articles for article (PubMed ID: 31830075)
1. Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment.
Hsu JC; Lin JY; Lin PC; Lee YC
PLoS One; 2019; 14(12):e0225938. PubMed ID: 31830075
[TBL] [Abstract][Full Text] [Related]
2. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
Angelis A; Montibeller G; Hochhauser D; Kanavos P
BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
4. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
[TBL] [Abstract][Full Text] [Related]
5. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
Hradecká I; Ríhová B; Horová R; Demlová R
Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
[TBL] [Abstract][Full Text] [Related]
6. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
Kwon SH; Park SK; Byun JH; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
8. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
Pettigrew M; Kavan P; Surprenant L; Lim HJ
J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
10. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
Carvalho AC; Leal F; Sasse AD
PLoS One; 2017; 12(4):e0175409. PubMed ID: 28403233
[TBL] [Abstract][Full Text] [Related]
13. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Mar; 13(3):233-4. PubMed ID: 22489288
[No Abstract] [Full Text] [Related]
14. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
15. A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies.
Lee J; Tollefson E; Daly M; Kielb E
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):361-70. PubMed ID: 23763533
[TBL] [Abstract][Full Text] [Related]
16. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
Kato S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
[TBL] [Abstract][Full Text] [Related]
17. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
Rautenberg T; Siebert U; Arnold D; Bennouna J; Kubicka S; Walzer S; Ngoh C
J Med Econ; 2014 Feb; 17(2):99-110. PubMed ID: 24215550
[TBL] [Abstract][Full Text] [Related]
18. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
[TBL] [Abstract][Full Text] [Related]
19. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]